Similarly, in the PRIMA trial, niraparib significantly improved survival outcomes in patients with homologous recombination deficiency (HRD), including those with BRCA1 or BRCA2 mutations, in newly diagnosed advanced ovarian cancer at high risk of recurrence [4,6]. This evidence concerns the gene BRCA2 and ovarian cancer.